Abstract
Paricalcitol, 19-nor-1, 25-dihydroxvitamin D2, is a novel 1,25–dihydroxyvitamin D2 analogue, which has greater potential to suppress parathyroid hormone without inducing significant hypercalcemia and hyperphosphatemia. We therefore investigated its role in treatment of patients with moderate to severe secondary hyperparathyroidism (SHPT) who were refractory to conventional therapy with Calcitriol and Cinacalcet HCl. Eight patients were recruited in whom conventional therapy was stable over the past 3 months. After a washout period of 2 weeks, calcijex injections were replaced by Paricalcitol. Paricalcitol induced more suppression of iPTH compared to the conventional therapy without significant hypercalcemia, hyperphosphatemia or side effects. The conversion ratio was approximately 1:2.5 (calcitriol:paricalcitol). In conclusion, injectable Paricalcitol is superior to Calcitriol in treatment of SHPT.
 Keywords: Cinacalcet, Calciferol, hemodialysis, hyperparathyroidism, Paricalcitol.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Journal of Drug Delivery and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
